Cidara Therapeutics Company Profile (NASDAQ:CDTX)

About Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics logoCidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CDTX
  • CUSIP: N/A
  • Web:
  • Market Cap: $120.57 million
  • Outstanding Shares: 16,863,000
Average Prices:
  • 50 Day Moving Avg: $6.71
  • 200 Day Moving Avg: $7.01
  • 52 Week Range: $5.60 - $12.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.35
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.63 per share
  • Price / Book: 2.09
  • EBIDTA: ($55,960,000.00)
  • Return on Equity: -75.72%
  • Return on Assets: -62.42%
  • Debt-to-Equity Ratio: 0.15%
  • Current Ratio: 7.49%
  • Quick Ratio: 7.49%
  • Average Volume: 124,738 shs.
  • Beta: 1.75
  • Short Ratio: 10.47

Frequently Asked Questions for Cidara Therapeutics (NASDAQ:CDTX)

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) issued its earnings results on Wednesday, August, 9th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.91) by $0.08. View Cidara Therapeutics' Earnings History.

Where is Cidara Therapeutics' stock going? Where will Cidara Therapeutics' stock price be in 2017?

10 brokerages have issued 1 year price targets for Cidara Therapeutics' stock. Their forecasts range from $7.25 to $20.00. On average, they expect Cidara Therapeutics' share price to reach $13.65 in the next twelve months. View Analyst Ratings for Cidara Therapeutics.

What are analysts saying about Cidara Therapeutics stock?

Here are some recent quotes from research analysts about Cidara Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (8/14/2017)
  • 2. Needham & Company LLC analysts commented, "Cidara mgmt provided a corporate update at an Investor Day in NYC last week and we separately hosted a series of mtgs w/ investors. Mgmt reiterated guidance for top-line results from ongoing Phase 2 trial of CD101 in Invasive Candida infections in 4Q17. The trial is expected to serve as the first of two registration trials. Given discontinuation of CD101 Vulvovaginal Candidiasis program, mgmt introduced plans to instead accelerate development in antifungal prophylaxis. KOLs highlighted differentiation from other echinocandins, w/ emphasis on PK/PD profile and opportunity for better clinical outcomes. New details around Cloudbreak candidates were also announced, although clinical testing not expected until 2018. Stock is attractive ahead of Phase 2 CD101 results later this year (EV $15M)." (4/10/2017)
  • 3. Cantor Fitzgerald analysts commented, "PD/PK Data Points to Success in Phase 2: Presentations reviewed the potency of CD101 against Candida and Aspergillus species as well as broad and sustained tissue distribution. We found the PK/PD optimized dosing data persuasive as it clearly demonstrates, effective AUC/MIC levels at the 400mg once-weekly over three weeks and 400mg loading dose followed by 200mg once weekly for two weeks, paralleling the two dosing regimens being studied in the Phase 2. We also note the potential for subcutaneous dosing, which could enhance the commercial story. We have increased our probability of success from 45% to 50%. Breadth of Cloudbreak Platform Highlighted: In addition to the antibacterial CD201, currently working through pre-IND studies, early in vivo/in vitro data was presented on a new antifungal asset." (4/7/2017)

Are investors shorting Cidara Therapeutics?

Cidara Therapeutics saw a decline in short interest during the month of August. As of August 15th, there was short interest totalling 536,961 shares, a decline of 53.3% from the July 31st total of 1,149,372 shares. Based on an average daily trading volume, of 109,766 shares, the short-interest ratio is currently 4.9 days. Currently, 5.6% of the shares of the company are short sold.

Who are some of Cidara Therapeutics' key competitors?

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the folowing people:

  • Scott M. Rocklage Ph.D., Chairman of the Board
  • Jeffrey Stein Ph.D., President, Chief Executive Officer, Director
  • Matthew W. Onaitis J.D., Chief Financial Officer, Principal Financial Officer, General Counsel, Secretary
  • Kenneth Bartizal Ph.D., Chief Development Officer
  • Paul Daruwala, Chief Commercial Officer
  • Kevin M. Forrest Ph.D., Chief Strategy Officer
  • Taylor Sandison M.D., Chief Medical Officer
  • Daniel D. Burgess, Director
  • Timothy R. Franson M.D., Director
  • Robert J. Perez, Director

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Who owns Cidara Therapeutics stock?

Cidara Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (8.76%), InterWest Venture Management Co (8.07%), Frazier Management LLC (7.78%), BB Biotech AG (6.56%), BROADFIN CAPITAL, LLC (5.28%) and Broadfin Capital LLC (4.84%). Company insiders that own Cidara Therapeutics stock include Jeffrey Stein, Kevin Forrest and Taylor Sandison. View Institutional Ownership Trends for Cidara Therapeutics.

Who sold Cidara Therapeutics stock? Who is selling Cidara Therapeutics stock?

Cidara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Vanguard Group Inc. and JPMorgan Chase & Co.. View Insider Buying and Selling for Cidara Therapeutics.

Who bought Cidara Therapeutics stock? Who is buying Cidara Therapeutics stock?

Cidara Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Goldman Sachs Group Inc., BB Biotech AG, Susquehanna International Group LLP, Trellus Management Company LLC, LMR Partners LLP, Raymond James Financial Services Advisors Inc. and Citadel Advisors LLC. Company insiders that have bought Cidara Therapeutics stock in the last two years include Jeffrey Stein, Kevin Forrest and Taylor Sandison. View Insider Buying and Selling for Cidara Therapeutics.

How do I buy Cidara Therapeutics stock?

Shares of Cidara Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cidara Therapeutics' stock price today?

One share of Cidara Therapeutics stock can currently be purchased for approximately $7.60.

MarketBeat Community Rating for Cidara Therapeutics (NASDAQ CDTX)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  307
MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cidara Therapeutics (NASDAQ:CDTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 8 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.65 (79.61% upside)

Analysts' Ratings History for Cidara Therapeutics (NASDAQ:CDTX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/11/2017Cantor FitzgeraldReiterated RatingOverweightHighView Rating Details
8/11/2017WBB SecuritiesUpgradeSell -> HoldLowView Rating Details
5/16/2017WedbushReiterated RatingOutperform$13.00LowView Rating Details
4/29/2017BTIG ResearchReiterated RatingBuy$15.00 -> $20.00LowView Rating Details
4/20/2017Raymond James Financial, Inc.Initiated CoverageStrong-Buy$14.00HighView Rating Details
4/17/2017HC WainwrightReiterated RatingBuy -> Buy$18.00 -> $14.00MediumView Rating Details
4/12/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$11.25LowView Rating Details
4/10/2017Needham & Company LLCReiterated RatingBuy$10.00MediumView Rating Details
3/24/2017Jefferies Group LLCReiterated RatingBuy$15.00HighView Rating Details
12/21/2016Leerink SwannInitiated CoverageOutperform$17.00N/AView Rating Details
(Data available from 9/23/2015 forward)


Earnings History for Cidara Therapeutics (NASDAQ:CDTX)
Earnings by Quarter for Cidara Therapeutics (NASDAQ:CDTX)
Earnings History by Quarter for Cidara Therapeutics (NASDAQ CDTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.91)($0.99)$0.25 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.90)($0.80)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.79)($0.88)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.89)($0.88)ViewN/AView Earnings Details
8/11/2016Q2($0.76)($0.85)ViewN/AView Earnings Details
5/12/2016Q1($0.76)($0.71)ViewN/AView Earnings Details
3/18/2016Q4 2015($0.70)($0.72)ViewN/AView Earnings Details
11/16/2015Q3($0.57)($0.67)ViewListenView Earnings Details
8/11/2015Q2 2015($0.59)($0.59)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cidara Therapeutics (NASDAQ:CDTX)
2017 EPS Consensus Estimate: ($3.64)
2018 EPS Consensus Estimate: ($2.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.93)($0.87)($0.90)
Q2 20172($0.89)($0.79)($0.84)
Q3 20172($1.02)($1.01)($1.02)
Q4 20172($1.00)($0.76)($0.88)
Q1 20181($0.78)($0.78)($0.78)
Q2 20181($0.79)($0.79)($0.79)
Q3 20181($0.80)($0.80)($0.80)
Q4 20181($0.59)($0.59)($0.59)
(Data provided by Zacks Investment Research)


Dividend History for Cidara Therapeutics (NASDAQ:CDTX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cidara Therapeutics (NASDAQ:CDTX)
Insider Ownership Percentage: 18.90%
Institutional Ownership Percentage: 66.10%
Insider Trades by Quarter for Cidara Therapeutics (NASDAQ:CDTX)
Institutional Ownership by Quarter for Cidara Therapeutics (NASDAQ:CDTX)
Insider Trades by Quarter for Cidara Therapeutics (NASDAQ:CDTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/12/2017Jeffrey SteinCEOBuy7,350$6.79$49,906.50View SEC Filing  
6/7/2017Taylor SandisonInsiderBuy20,000$5.90$118,000.00View SEC Filing  
6/5/2017Jeffrey SteinCEOBuy15,000$5.95$89,250.00View SEC Filing  
3/31/2017Jeffrey SteinCEOBuy12,900$7.75$99,975.00View SEC Filing  
3/31/2017Kevin ForrestInsiderBuy12,500$7.75$96,875.00View SEC Filing  
5/20/2016Jeffrey SteinCEOBuy4,310$11.51$49,608.10View SEC Filing  
5/20/2016Kevin ForrestCFOBuy4,356$11.53$50,224.68View SEC Filing  
11/25/2015Jeffrey SteinCEOBuy6,700$15.09$101,103.00View SEC Filing  
11/23/2015Kevin ForrestCFOBuy7,087$14.23$100,848.01View SEC Filing  
4/20/2015Timothy R FransonDirectorBuy4,000$16.00$64,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cidara Therapeutics (NASDAQ:CDTX)
Latest Headlines for Cidara Therapeutics (NASDAQ:CDTX)
DateHeadline logoCidara Therapeutics to Present at Two Upcoming Conferences - September 18 at 8:37 PM logoCidara Therapeutics, Inc. (CDTX) Receives Average Recommendation of "Buy" from Brokerages - September 17 at 4:46 PM logoCidara Therapeutics, Inc. (CDTX) CEO Acquires $49,906.50 in Stock - September 12 at 8:24 PM logoCidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress - September 7 at 5:09 PM logoAntimicrobials Working Group Member Companies Announce Partnership and Exclusive Pricing Program - September 6 at 10:05 PM logoCidara Therapeutics, Inc. (CDTX) Downgraded by ValuEngine to Strong Sell - September 3 at 7:08 PM logoCidara Therapeutics, Inc. (CDTX) Short Interest Down 53.3% in August - August 28 at 1:20 AM logoCidara Therapeutics, Inc. (CDTX) Receives Consensus Recommendation of "Buy" from Analysts - August 23 at 6:46 PM logoBrokers Issue Forecasts for Cidara Therapeutics, Inc.'s Q3 2017 Earnings (CDTX) - August 16 at 7:22 AM logoCidara Therapeutics, Inc. (CDTX) Stock Rating Lowered by Zacks Investment Research - August 14 at 6:38 PM logoEquities Analysts Offer Predictions for Cidara Therapeutics, Inc.'s FY2018 Earnings (CDTX) - August 14 at 9:22 AM logoLeerink Swann Comments on Cidara Therapeutics, Inc.'s Q3 2017 Earnings (NASDAQ:CDTX) - August 14 at 3:34 AM logoCidara Therapeutics' (CDTX) Overweight Rating Reiterated at Cantor Fitzgerald - August 12 at 6:34 AM logoCidara Therapeutics, Inc. (CDTX) Upgraded to "Hold" at WBB Securities - August 11 at 7:32 PM logoCantor Fitzgerald Analysts Give Cidara Therapeutics, Inc. (CDTX) a $15.00 Price Target - August 10 at 6:20 PM logoCidara Therapeutics Inc (NASDAQ:CDTX) Announces Quarterly Earnings Results - August 9 at 11:58 PM logoCidara Therapeutics reports 2Q loss - August 9 at 10:17 PM logoCidara Therapeutics Announces Publication of Results from In Vivo Study Investigating Novel Antifungal CD101 in Intra-Abdominal Candidiasis (IAC) - August 1 at 3:34 PM logoCidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of "Buy" by Analysts - July 29 at 4:43 PM logoCidara Therapeutics, Inc. (NASDAQ:CDTX) Stock Rating Upgraded by ValuEngine - July 15 at 12:16 AM logoZacks Investment Research Downgrades Cidara Therapeutics, Inc. (CDTX) to Hold - July 12 at 4:46 PM logoZacks Investment Research Upgrades Cidara Therapeutics, Inc. (CDTX) to "Buy" - July 11 at 6:40 PM logoCidara Therapeutics to Participate in Anti-Infectives Panel Discussion at the 2017 Infectious Diseases Summit - July 6 at 6:16 PM logoCidara Therapeutics, Inc. (CDTX) Given Average Rating of "Buy" by Brokerages - July 4 at 5:22 PM logoCidara Therapeutics, Inc. (CDTX) Receives New Coverage from Analysts at Cantor Fitzgerald - June 26 at 10:31 AM logoCidara Therapeutics, Inc. (CDTX) Lowered to Hold at Zacks Investment Research - June 20 at 6:38 PM logoCidara Therapeutics, Inc. (CDTX) Stock Rating Upgraded by Zacks Investment Research - June 19 at 7:00 PM logoAntimicrobial Working Group Members to Participate in 2017 BIO International Convention Panel - June 19 at 2:11 PM logoCidara Therapeutics to Participate in the 2017 BIO International Convention - June 15 at 5:59 PM logoShort Interest in Cidara Therapeutics, Inc. (CDTX) Rises By 42.7% - June 13 at 7:04 AM logoCidara Therapeutics Inc (CDTX) Given Consensus Recommendation of "Buy" by Analysts - June 9 at 7:02 PM logoCidara Therapeutics Inc (CDTX) Insider Taylor Sandison Buys 20,000 Shares - June 8 at 7:52 PM logoCidara Therapeutics Inc (CDTX) CEO Acquires $89,250.00 in Stock - June 7 at 8:20 PM logoCidara Therapeutics Inc (CDTX) Lowered to Strong Sell at ValuEngine - June 5 at 10:34 PM logoCidara Therapeutics Inc (CDTX) Given a $11.00 Price Target at Cantor Fitzgerald - June 5 at 3:40 PM logoCidara Therapeutics Announces Presentations at ASM Microbe 2017 and the 22nd Congress of the European Hematology Association - May 30 at 12:07 PM logoCidara Therapeutics Inc (CDTX) Earns Outperform Rating from Wedbush - May 16 at 8:14 AM logoCidara Therapeutics Inc (CDTX) Given Average Recommendation of "Buy" by Analysts - May 15 at 2:46 PM logoCidara Therapeutics Inc (CDTX) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS - May 10 at 10:58 PM logoCidara Provides Corporate Update and Reports First Quarter 2017 Financial Results - May 10 at 9:27 PM logoCidara Therapeutics reports 1Q loss - May 10 at 9:27 PM logoIs a Surprise Coming for Cidara Therapeutics (CDTX) This Earnings Season? - May 10 at 4:25 PM logoCidara Therapeutics Inc (CDTX) Expected to Post Earnings of -$0.88 Per Share - May 3 at 6:02 PM logoCidara Therapeutics (CDTX) Earning Somewhat Positive Press Coverage, Report Finds - May 2 at 12:52 PM logoCidara Therapeutics Inc (CDTX) Stock Rating Reaffirmed by BTIG Research - April 29 at 9:57 PM logoCidara Therapeutics (CDTX) Earning Somewhat Positive Media Coverage, Analysis Finds - April 29 at 2:03 PM logoCidara Therapeutics (CDTX) Earns Daily Media Sentiment Score of 0.16 - April 26 at 10:18 PM logoCidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer - April 25 at 12:19 PM logoCantor Fitzgerald Reaffirms "Buy" Rating for Cidara Therapeutics Inc (CDTX) - April 24 at 11:20 PM logoCidara Therapeutics (CDTX) Given Daily Media Impact Rating of 0.04 - April 23 at 2:57 PM



Cidara Therapeutics (CDTX) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by Staff